Future of Celera's KIF6 Test Unclear Amid FDA Rejection, Pending Quest Acquisition | GenomeWeb

Originally published April 26.

By Turna Ray

Amid mounting evidence against the utility of its KIF6 Genotyping Assay, Celera is hoping to meet with the US Food and Drug Administration to discuss the regulatory status of the test after the agency deemed it "not approvable."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.